Original Article
A Comparison of Risperidone and Haloperidol for the Prevention of Relapse in Patients with Schizophrenia
N Engl J Med 2002; 346:16-22January 3, 2002
- Abstract
Background
Prevention of relapse is a major goal of maintenance treatment in patients with psychotic disorders. We performed a long-term comparison of a newer, atypical antipsychotic drug, risperidone, and an older, conventional neuroleptic drug, haloperidol, in terms of the rate of relapse in patients with schizophrenia and schizoaffective disorder.
Methods
In a double-blind, prospective study at 40 sites, we randomly assigned adult outpatients in stable condition with chronic schizophrenia or schizoaffective disorder to receive treatment with flexible doses of either risperidone or haloperidol for a minimum of one year.
Results
Of the 397 patients who underwent randomization, data from 2 were excluded because they did not receive study medication; data from all 30 patients from one site were excluded by the sponsor, the Janssen Research Foundation, because of concern about the integrity of the data. The median duration of treatment was 364 days in the risperidone group and 238 days in the haloperidol group (P=0.02). Of the 177 patients assigned to risperidone and the 188 assigned to haloperidol who remained in the analysis, 44.1 percent and 52.7 percent, respectively, discontinued treatment for reasons other than relapse. The Kaplan–Meier estimate of the risk of relapse at the end of the study was 34 percent for the risperidone group and 60 percent for the haloperidol group (P<0.001); the risk ratio for relapse with haloperidol, from the Cox model, was 1.93 (95 percent confidence interval, 1.33 to 2.80; P<0.001). Early discontinuation of treatment for any reason was more frequent among haloperidol-treated patients (risk ratio, 1.52; 95 percent confidence interval, 1.18 to 1.96). Patients in the risperidone group had greater reductions in the mean severity of both psychotic symptoms and extrapyramidal side effects than those in the haloperidol group.
Conclusions
Adult outpatients with clinically stable schizophrenia or schizoaffective disorder have a lower risk of relapse if they are treated with risperidone than if they are treated with haloperidol.
Media in This Article
Figure 2
Mean (±SE) Changes from Base Line to the End of the Study in Total and Factor Scores on the Positive and Negative Syndrome Scale for Schizophrenia in Patients Assigned to Risperidone or Haloperidol.Figure 1
Kaplan–Meier Analysis of Time to Relapse in Patients Assigned to Risperidone or Haloperidol.Article Activity
- Article
Schizophrenia is a chronic illness with a lifetime prevalence of 0.7 percent in the United States1 and with serious physical, social, and economic consequences.2 The economic burden of schizophrenia on society was estimated as $33 billion in the United States in 1990.3 Much of this cost was attributed to the consequences of psychotic relapse.4 The course of schizophrenia varies,5 but most patients have a chronic course with frequent relapses, typically characterized by exacerbation of psychosis and rehospitalization. Successive relapses can reduce the degree and duration of the next remission, worsen disability, and increase refractoriness to future treatment.6 To prevent relapse, maintenance treatment with antipsychotic drugs is obligatory for most patients who have schizophrenia or schizoaffective disorder.7 Nevertheless, long-term outcomes have generally been disappointing.8,9
Drugs referred to as atypical antipsychotic drugs are antagonists at both dopamine and serotonin receptors in the central nervous system; in contrast, conventional agents act predominantly at the dopamine receptor.10 Although considered a class of drugs, these atypical agents (clozapine, risperidone, olanzapine, and quetiapine) differ in their receptor-binding profiles10 and clinical effects. Some authors have expressed doubt that atypical antipsychotic drugs offer any advantages beyond improved tolerability11,12 and therefore argue for the continued use of conventional agents.
The results of short-term studies indicate that all available atypical antipsychotic drugs (clozapine, risperidone, olanzapine, and quetiapine) are more effective than the conventional antipsychotic drug haloperidol for the treatment of “negative” schizophrenic symptoms, such as withdrawal from social interactions and blunted emotional expression.13-16 For “positive” symptoms, such as hallucinations and delusions, risperidone was found to be superior to haloperidol in a combined analysis of large controlled trials.17 We therefore hypothesized that treatment with risperidone would be superior to haloperidol in reducing the risk of relapse among outpatients with schizophrenia or schizoaffective disorder.18
Methods
Patients
Eligibility criteria included an age of 18 to 65 years, a diagnosis of schizophrenia or schizoaffective disorder according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV),19 and inpatient psychiatric hospitalization, daytime psychiatric hospitalization, outpatient crisis management, or short-term treatment in a psychiatric hospital emergency room within the 24 months before study entry. All patients had received a stable dose of antipsychotic medication for at least 30 days before entry, had resided at the same address for at least 30 days before entry, and were judged clinically stable by the principal investigator at each site. Exclusion criteria included another current DSM-IV Axis I diagnosis, an Axis II diagnosis of borderline personality disorder or antisocial personality disorder, current substance dependence or abuse, clinically significant or unstable medical illness, current treatment with clozapine, a history of refractoriness to antipsychotic drugs, and treatment with depot neuroleptic injections within one treatment cycle before screening. Patients who were allergic to either risperidone or haloperidol and women who were pregnant or nursing were also excluded.
The study protocol was approved by an institutional review board at each site, and each patient or his or her legal guardian provided written informed consent for participation.
Procedure
During the period from May 1996 to September 1998, patients were randomly assigned to double-blind treatment with risperidone (Risperdal, Janssen, Titusville, N.J.) or haloperidol (Haldol, Ortho-McNeil, Raritan, N.J.). To minimize possible adverse events associated with the discontinuation of medication that the patients were taking before the trial began, the gradual reduction of such antipsychotic drugs was permitted during days 1 to 7. During days 1 to 3, doses were increased from 1 mg to 4 mg of risperidone per day and from 2 mg to 10 mg of haloperidol per day. Both drugs were given once daily. From day 8 onward, investigators at each site adjusted the doses of identical-appearing tablets (range of permissible doses, 2 to 8 mg of risperidone per day and 5 to 20 mg of haloperidol per day) to maximize clinical benefits and minimize adverse events. Lower doses (e.g., 1 mg of risperidone per day or 2.5 mg of haloperidol per day) were permitted in rare cases. Concomitant medications were not allowed, except for antacids; acetaminophen; propranolol, benztropine mesylate, biperiden, or procyclidine for extrapyramidal symptoms caused by treatment; chloral hydrate, zolpidem, or flurazepam to improve sleep; and lorazepam for agitation, in doses not exceeding 4 mg per day for no more than four days in any seven-day period.
Patients were assessed weekly during the first four weeks of the trial and then every four weeks until the last patient enrolled had completed one year of treatment. Because of concern that the prospect of discontinuation of treatment and dismissal from the study could influence reporting of relapses, a patient who had a relapse could attend the remaining scheduled study visits if both the patient and the investigator wished. However, all patients who had a second relapse were removed from the trial and no longer followed for any study outcome.
The investigators at participating academic institutions contributed to the design of the study, had full access to the study data base, and were involved in data analysis and interpretation. Investigators from the Janssen Research Foundation, the developer of both risperidone and haloperidol, also participated in the design, analysis, and reporting of the trial.
Assessment of Outcomes
We calculated relapse rates and time to first relapse. Relapse was defined by any one of the following: psychiatric hospitalization; an increase in the level of psychiatric care (e.g., from clinic visits to day treatment) and an increase of 25 percent from base line in the total score on the Positive and Negative Syndrome Scale,20 or an increase of 10 points if the base-line score was 40 or less (total possible scores range from 30 to 210, with higher scores indicating greater severity of symptoms); deliberate self-injury; suicidal or homicidal ideation that was clinically significant in the investigator's judgment; violent behavior resulting in clinically significant injury to another person or property damage; or substantial clinical deterioration, defined as a change score of 6 (“much worse”) or 7 (“very much worse”) on the Clinical Global Impressions Scale (possible scores range from 1 to 7, with a score of 4 indicating no change, 1 to 3 improvement, and 5 to 7 worsening).21 Secondary outcome measures included the total score and five factor scores from the Positive and Negative Syndrome Scale,17 including positive symptoms, negative symptoms, anxiety–depression, hostility–excitement, and disorganized thoughts.
Safety assessments included monitoring for adverse events, a battery of standard laboratory tests, electrocardiography, and physical examination. Extrapyramidal symptoms were assessed with the Extrapyramidal Symptom Rating Scale (total possible scores range from 0 to 162, with higher scores indicating greater severity of adverse effects).22 A patient questionnaire is included within this scale; the scores range from 0 to 36, with higher scores indicating greater perception of adverse effects.
Statistical Analysis
The sample sizes were selected to make possible the detection of a 15 percent difference in relapse rates after one year with 80 percent power and a two-tailed level of significance of 0.05 (165 patients per treatment group). The sample sizes were then increased to 207 per group to account for a 20 percent rate of dropout for reasons other than relapse. Primary analyses were performed on all subjects who underwent randomization and were assessed at least once during drug treatment. Base-line characteristics and duration of treatment were compared between the two groups by analysis of variance or the Cochran–Mantel–Haenszel test.23 Duration of treatment and follow-up were summarized by descriptive statistics.
Differences in time to relapse between treatment groups were analyzed with use of a Cox proportional-hazards model and a log-rank test23 with control for site and sex. Follow-up for end points ceased after the discontinuation of treatment, and data for the analysis of time to relapse were therefore censored at the time of discontinuation of treatment. Risk ratios and reductions in risk (with corresponding confidence intervals) were derived with use of the Cox model. Differences between the groups in the degree of change in scores on the Positive and Negative Syndrome Scale and Extrapyramidal Symptom Rating Scale from base line to the last assessment were studied by analysis of covariance. All statistical tests were two-tailed.
Results
A total of 397 patients were recruited at 40 sites and randomly assigned to double-blind treatment with either risperidone or haloperidol. The data on two patients assigned to risperidone who did not receive study medication were excluded from analysis. The data from all 30 patients at another site were also excluded, because the principal investigator at that site did not conduct the trial in a manner that was consistent with restrictions previously placed on him by the Food and Drug Administration (FDA) after an inspection by the FDA. The restrictions were intended to ensure the integrity of the data in the trial. The decision to exclude the data from this site was made by the quality-assurance department of Janssen Research Foundation and not by a committee of the authors. The quality-assurance department did not know to which treatment patients had been assigned. Exclusion of the data from this site did not change the findings regarding the primary end point (data not shown). Data from the remaining 365 patients were included in the final analysis.
Characteristics of Patients and Withdrawals
The characteristics of the 365 patients in the two treatment groups were similar (Table 1Table 1
Base-Line Characteristics of the 365 Patients.). Most patients had had a diagnosis of schizophrenia and had been ill for more than a decade. The median duration of treatment was 364 days (range, 3 to 799) in the risperidone group and 238 days (range, 4 to 794) in the haloperidol group (P=0.02 by analysis of variance).The rate of premature discontinuation of study treatment for any reason was higher in the haloperidol group than in the risperidone group (risk ratio, 1.52; 95 percent confidence interval, 1.18 to 1.96). The reasons for discontinuation, other than relapse, were similar in the two treatment groups: the patient's choice in 18.1 percent in the risperidone group and 17.6 percent in the haloperidol group; adverse events in 12.4 percent and 15.4 percent, respectively; loss to follow-up in 5.1 percent and 4.8 percent; poor compliance in 2.8 percent and 5.3 percent; inadequate response in 1.1 percent and 3.7 percent; administrative reasons in 2.8 percent and 1.1 percent; and other reasons in 1.7 percent and 4.8 percent.
Dosage and Compliance
The means (±SD) of the modal daily doses were 4.9±1.9 mg of risperidone and 11.7±5.0 mg of haloperidol. The modal daily doses of risperidone were less than 4 mg in 12.4 percent of patients, 4 to 6 mg in 68.4 percent, and 8 mg in 19.2 percent. The modal daily doses of haloperidol were 2.5 to 5 mg in 19.1 percent of patients, 7.5 to 10 mg in 44.1 percent, and 15 to 20 mg in 36.7 percent.
Almost all patients were found to be compliant with the study medication regimen, as assessed by pill count (97.0 percent of patients taking risperidone and 96.0 percent of patients taking haloperidol). Compliance was also high according to pill count in the 30 days before relapse among patients who had relapses (95.3 percent of the risperidone group and 95.2 percent of the haloperidol group were compliant).
Relapse
At the end of the study, 25.4 percent of patients in the risperidone group (45 of 177) and 39.9 percent of patients in the haloperidol group (75 of 188) had relapsed (Figure 1Figure 1
Kaplan–Meier Analysis of Time to Relapse in Patients Assigned to Risperidone or Haloperidol.). The Kaplan–Meier estimate of the risk of relapse was 34 percent (95 percent confidence interval, 28 to 43 percent) in the risperidone group and 60 percent (95 percent confidence interval, 50 to 70 percent) in the haloperidol group (P<0.001). The risk of relapse was substantially higher among patients assigned to haloperidol (risk ratio, 1.93; 95 percent confidence interval, 1.33 to 2.80; P<0.001). For patients assigned to risperidone, the relapse rate represented a 48 percent reduction in risk (95 percent confidence interval, 25 to 64 percent) as compared with haloperidol treatment.The Kaplan–Meier estimates of the relapse rates were similar in patients with schizophrenia (34 percent for the risperidone group and 59 percent for the haloperidol group) and in those with schizoaffective disorder (34 percent and 62 percent, respectively). The subtypes of relapse were similar in the two groups of patients: psychiatric hospitalization in 44 percent and 48 percent, respectively; substantial clinical deterioration in 36 percent and 29 percent; an increase in level of care in 18 percent and 19 percent; and suicidal or homicidal ideation in 2 percent and 4 percent.
Before the study, 25 percent of patients were receiving risperidone, 27 percent haloperidol, and 48 percent other conventional antipsychotic medications. To assess the effect of the change in treatment caused by random assignment to another drug in these stable outpatients, patients assigned to a new treatment were compared with patients whose treatment was unchanged. Switching therapy had no effect on the estimated relapse rates at the end of the study; 29 percent of patients who were switched from haloperidol to risperidone had relapsed, as compared with 60 percent of patients switched from risperidone to haloperidol; 28 percent of patients who continued to take risperidone had relapsed, as compared with 60 percent who continued to take haloperidol.
Symptom Scales
The overall reduction in symptoms was smaller than that reported in previous studies of patients with acute exacerbations of schizophrenia, as would be expected in patients with stable disease. Significant differences between subjects assigned to risperidone and those assigned to haloperidol were seen in total scores on the Positive and Negative Syndrome Scale and in four of the five factor scores at the last study rating (Figure 2Figure 2
Mean (±SE) Changes from Base Line to the End of the Study in Total and Factor Scores on the Positive and Negative Syndrome Scale for Schizophrenia in Patients Assigned to Risperidone or Haloperidol.). In the risperidone group, improvements from base line to one year or to the last study rating were seen in total scores and in positive symptoms, negative symptoms, disorganized thoughts, and anxiety–depression. In the haloperidol group, symptoms were not improved over base line. In post hoc analyses, patients in the risperidone group had a significant improvement from base line in symptoms after one week of double-blind treatment: the changes in total scores on the Positive and Negative Syndrome Scale were a decrease of 3.7 in the risperidone group (P<0.001) and a decrease of 1.1 in the haloperidol group (P=0.17).Extrapyramidal Symptoms
The severity of extrapyramidal symptoms was reduced from base line to the last recorded value in the risperidone group and increased in the haloperidol group (Table 2Table 2
Scores on the Extrapyramidal Symptom Rating Scale at Base Line and Least-Squares Mean Changes from Base Line to the Last Recorded Value.). Differences between the groups were significant on each measure on the Extrapyramidal Symptom Rating Scale. Antiparkinsonian drugs were prescribed for 30 consecutive days for twice as many patients assigned to haloperidol (33 of 188 [17.6 percent]) as patients assigned to risperidone (16 of 177 [9.0 percent], P=0.02 by the Cochran–Mantel–Haenszel test). The new onset of tardive dyskinesia was reported in one patient assigned to risperidone (0.6 percent) and five assigned to haloperidol (2.7 percent).Adverse Events and Body-Weight Changes
Adverse events were identified in 89.8 percent of patients assigned to risperidone and 91.0 percent of those assigned to haloperidol. The events reported in more than 10 percent of subjects in at least one group were somnolence (14 percent with risperidone and 25 percent with haloperidol), agitation (10 percent and 18 percent, respectively), and hyperkinesia (5 percent and 20 percent). There was a mean increase in body weight of 2.3 kg (5.0 lb) in patients assigned to risperidone — similar in magnitude to the weight gain seen in short-term studies — and a mean decrease of 0.73 kg (1.6 lb) in patients assigned to haloperidol (P<0.001).
Discussion
Among patients with clinically stable chronic schizophrenia or schizoaffective disorder, the risk of relapse was significantly lower during treatment with risperidone than during treatment with haloperidol. The benefit with risperidone was substantial. The means of the modal daily doses of risperidone (4.9 mg) and haloperidol (11.7 mg) were similar to those used in clinical practice. The relapse rate among subjects receiving haloperidol (39.9 percent) was similar in magnitude to that found previously among patients receiving conventional antipsychotic agents.4,24
The reduced risk of relapse with risperidone could be due to that drug's superior efficacy, better tolerability, or both. Patients who received risperidone had both early and late improvements in symptoms overall, as well as an amelioration of extrapyramidal symptoms. In contrast, patients receiving haloperidol had a slight worsening of both psychotic and extrapyramidal symptoms. These findings are similar to those previously reported for an eight-week comparative trial of risperidone and haloperidol.14,17 In our trial, compliance with the study medication, which can also influence the rate of relapse,25 was similar in the two treatment groups. Improvements in cognition or other symptoms of schizophrenia produced by risperidone but not well assessed by the Positive and Negative Syndrome Scale may also have contributed to the reductions in the rate of relapse.
Receptor profiles and mechanisms of action vary among atypical antipsychotic agents.10 Therefore, other agents should be assessed individually with regard to their ability to prevent relapses.
The longer duration of drug treatment with risperidone than with haloperidol appeared to be the result of lower rates of relapse in patients receiving risperidone, since the rates of other reasons for discontinuation were similar in the two treatment groups. Analysis of the time to relapse (Figure 1) suggested that the benefits of risperidone over haloperidol appeared early and grew progressively larger throughout the trial. Thus, the full clinical benefits of treatment with an antipsychotic drug should be judged over an extended period.
A limitation of our study is the number of patients who left the trial. To the extent that such discontinuation is dependent on the treatment assignment, bias may be introduced. The reasons for discontinuation did not differ between treatment groups, and the differences between the groups in the effects of treatment appeared early, grew consistently with time, and were substantial.
In our study, patients with chronic but stable schizophrenia were randomly assigned to treatment, in contrast to studies in which patients successfully treated in a short-term trial were continued on the same antipsychotic agent.26,27 Our results demonstrate that substantial reductions in the risk of relapse can be achieved in such patients with the use of risperidone, even in comparison with the use of an effective conventional antipsychotic.
Supported by Janssen Research Foundation. Dr. Csernansky has received research grant support and honorariums for delivering lectures from Janssen Research Foundation, Eli Lilly, AstraZeneca Pharmaceuticals, and Pfizer Pharmaceuticals. Dr. Brenner has received research support from Janssen Research Foundation, Eli Lilly, AstraZeneca Pharmaceuticals, and Pfizer Pharmaceuticals.
Source Information
From Washington University School of Medicine and Metropolitan St. Louis Psychiatric Center, St. Louis (J.G.C.); Janssen Research Foundation, Titusville, N.J. (R.M.); and St. John's Episcopal Hospital, Far Rockaway, N.Y. (R.B.).
Address reprint requests to Dr. Csernansky at the Department of Psychiatry, Washington University School of Medicine, Box 8134, 660 S. Euclid Ave., St. Louis, MO 63110-1081, or at csernanj@medicine.wustl.edu.
Investigators in the study are listed in the Appendix.
Appendix
The following investigators participated in the Risperidone-USA-79 Study: F. Adan, Miami; D. Brown, Austin, Tex.; J. Chou, New York; C. Cohn, Houston; M. DePriest and B. Cole, Las Vegas; L. Dunn, Durham, N.C.; W. Goodman and M. Byerly, Gainesville, Fla.; A.I. Green and D.A. Klegon, Boston; R.M. Hamer and M. Menza, Piscataway, N.J.; M. Hamner, Charleston, S.C.; H. Harsch, Milwaukee; G.G. Jaskiw, Brecksville, Ohio; B. Johnson, Houston; A. Kiev, Englewood, N.J.; I.S. Kolin, Winter Park, Fla.; M.A. Knesevich, Dallas; A. Kopelowicz, Mission Hills, Calif.; D. Levinson, Philadelphia; H.E. Logue, Birmingham, Ala.; M.J. Miller, Indianapolis; R. Nakra, Chesterfield, Mo.; G. Pahl, Oklahoma City; M. Plopper, San Diego, Calif.; S. Preskorn, Wichita, Kans.; G. Simpson, Los Angeles; S. Strakowski, Cincinnati; M. Thomas, Denver; S.A. West, Orlando, Fla.; J. Yaryura-Tobias, Great Neck, N.Y.; and T.P. Yoo, Detroit.
- References
References
1
Kendler KS ,Gallagher TJ ,Abelson JM ,Kessler RC . Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample: the National Comorbidity Survey. Arch Gen Psychiatry 1996;53:1022-1031
Web of Science | Medline2
Buckley PF . Treatment of schizophrenia: let's talk dollars and sense. Am J Manag Care 1998;4:369-383[Erratum, Am J Manag Care 1998;4:611.]
Web of Science | Medline3
Rice DP . The economic impact of schizophrenia. J Clin Psychiatry 1999;60:Suppl 1:4-6
Web of Science | Medline4
Weiden PJ ,Olfson M . Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-429
Web of Science | Medline5
Andreasen NC . Symptoms, signs, and diagnosis of schizophrenia. Lancet 1995;346:477-481
CrossRef | Web of Science | Medline6
Wyatt RJ . Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991;17:325-351
Web of Science | Medline7
Kane JM . Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999;46:1396-1408
CrossRef | Web of Science | Medline8
Herz MI ,Lamberti JS ,Mintz J , et al. A program for relapse prevention in schizophrenia: a controlled study. Arch Gen Psychiatry 2000;57:277-283
CrossRef | Web of Science | Medline9
Ayuso-Gutierrez JL ,del Rio Vega J . Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997;28:199-206
CrossRef | Web of Science | Medline10
Richelson E . Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996;57:Suppl 11:4-11
Web of Science | Medline11
Mattes JA . Risperidone: how good is the evidence for efficacy? Schizophr Bull 1997;23:155-161
Web of Science | Medline12
Mattes JA . Olanzapine on trial. Am J Psychiatry 1998;155:153-153
Web of Science | Medline13
Kane J ,Honigfeld G ,Singer J ,Meltzer H . Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
CrossRef | Web of Science | Medline14
Marder SR ,Meibach RC . Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
Web of Science | Medline15
Beasley CM Jr ,Tollefson G ,Tran P ,Satterlee W ,Sanger T ,Hamilton S . Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
CrossRef | Web of Science | Medline16
Arvanitis LAS ,Miller BG . Multiple fixed doses of “Seroquel“ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
CrossRef | Web of Science | Medline17
Marder SR ,Davis JM ,Chouinard G . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-546[Erratum, J Clin Psychiatry 1998;59:200.]
CrossRef | Web of Science | Medline18
Marder SR . Antipsychotic drugs and relapse prevention. Schizophr Res 1999;35:Suppl:S87-S92
CrossRef | Web of Science | Medline19
Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington, D.C.: American Psychiatric Association, 1994.
20
Kay SR ,Fiszbein A ,Opler LA . The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
Web of Science | Medline21
Guy W, ed. ECDEU assessment manual for psychopharmacology. Rev. ed. Rockville, Md.: National Institute of Mental Health, Psychopharmacology Research Branch, 1976. (DHEW publication no. (ADM) 76-338.)
22
Chouinard G ,Ross-Chouinard A ,Annable L ,Jones BD . Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980;7:233-233 abstract.
Web of Science23
Lang TA, Secic M. How to report statistics in medicine: annotated guidelines for authors, editors, and reviewers. Philadelphia: American College of Physicians, 1997:249, 252.
24
Hogarty GE ,Ulrich RF . The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 1998;32:243-250
CrossRef | Web of Science | Medline25
Fenton WS ,Blyler CR ,Heinssen RK . Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651
Web of Science | Medline26
Moller H-J ,Gagiano CA ,Addington DE ,von Knorring L ,Torres-Plank JF ,Gaussares C . Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. Int Clin Psychopharmacol 1998;13:99-106
CrossRef | Web of Science | Medline27
Dellva MA ,Tran P ,Tollefsen GD ,Wentley AL ,Beasley CM Jr . Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997;48:1571-1577
Web of Science | Medline
- Citing Articles (191)
Citing Articles
1
Terence K.Y. Lai, Philip Seeman, Fang Liu. (2012) Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia. Synapse 66:3, 273-276
CrossRef2
Yu-Tao Xiang, Chuan-Yue Wang, Yong-Zhen Weng, Qi-Jing Bo, Helen F. K. Chiu, Sandra S. M. Chan, Edwin H. M. Lee, Gabor S. Ungvari. (2011) Predictors of relapse in Chinese schizophrenia patients: a prospective, multi-center study. Social Psychiatry and Psychiatric Epidemiology 46:12, 1325-1330
CrossRef3
Christoph U. Correll, Taishiro Kishimoto, Jimmi Nielsen, John M. Kane. (2011) Quantifying Clinical Relevance in the Treatment of Schizophrenia. Clinical Therapeutics 33:12, B16-B39
CrossRef4
T Kishimoto, V Agarwal, T Kishi, S Leucht, J M Kane, C U Correll. (2011) Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Molecular Psychiatry
CrossRef5
María Fe Bravo-Ortiz, José Ramón Gutiérrez-Casares, Alexander Rodríguez-Morales, Mario Alberto Peña García, Rebeca Hidalgo-Borrajo. (2011) Influence of type of treatment on the well-being of Spanish patients with schizophrenia and their caregivers. International Journal of Psychiatry in Clinical Practice 15:4, 286-295
CrossRef6
Louis S. Matza, Glenn A. Phillips, Dennis A. Revicki, Haya Ascher-Svanum, Dawn Kaiser, Virginia Stauffer, Jodi M. Shorr, Bruce J. Kinon. (2011) Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation. Psychiatry Research 189:3, 463-468
CrossRef7
Rosario Arce Cordón, Evelin Eding, Joao Marques-Teixeira, Vihra Milanova, Elmars Rancans, Andreas Schreiner. (2011) Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical Neuroscience
CrossRef8
Xiaofeng Guo, Maosheng Fang, Jinguo Zhai, Bo Wang, Chuanyue Wang, Bin Hu, Xueli Sun, Luxian Lv, Zheng Lu, Cui Ma, Tiansheng Guo, Shiping Xie, Elizabeth W. Twamley, Hua Jin, Jingping Zhao. (2011) Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study. Psychopharmacology 216:4, 475-484
CrossRef9
Tom Stargardt, Paraskevi Mavrogiorgou, Christian A. Gericke, Georg Juckel. (2011) Effectiveness and costs of flupentixol compared to other first- and second-generation antipsychotics in the treatment of schizophrenia. Psychopharmacology 216:4, 579-587
CrossRef10
Yu-Tao Xiang, Chuan-Yue Wang, Helen F. K. Chiu, Yong-Zhen Weng, Qi-Jing Bo, Sandra S. M. Chan, Edwin H. M. Lee, Gabor S. Ungvari. (2011) Socio-Demographic and Clinical Profiles of Paranoid and Nonparanoid Schizophrenia: A Prospective, Multicenter Study in China. Perspectives in Psychiatric Care 47:3, 126-130
CrossRef11
(2011) Long-Acting Risperidone and Oral Antipsychotics in Schizophrenia. New England Journal of Medicine 364:23, 2264-2266
Full Text12
Benedicto Crespo-Facorro, Rocío Pérez-Iglesias, Ignacio Mata, Olalla Caseiro, Obdulia Martínez-Garcia, Gema Pardo, MariLuz Ramirez-Bonilla, Jose Maria Pelayo-Terán, José L. Vázquez-Barquero. (2011) Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine. Journal of Psychiatric Research 45:6, 763-769
CrossRef13
Nicolas M. Furiak, Haya Ascher-Svanum, Robert W. Klein, Lee J. Smolen, Anthony H. Lawson, William Montgomery, Robert R. Conley. (2011) Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Current Medical Research and Opinion 27:4, 713-730
CrossRef14
Sheng Chen, Philip Seeman, Fang Liu. (2011) Antipsychotic drug binding in the substantia nigra: An examination of high metoclopramide binding in the brains of normal, Alzheimer's disease, Huntington's disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia. Synapse 65:2, 119-124
CrossRef15
Daniel Tarsy, Codrin Lungu, Ross J. Baldessarini. 2011. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. , 601-616.
CrossRef16
Stanley Fahn, Joseph Jankovic, Mark Hallett. 2011. The tardive syndromes. , 415-446.
CrossRef17
John R. Geddes, T. Scott Stroup, Jeffrey A. Lieberman. 2010. Comparative Efficacy and Effectiveness in the Drug Treatment of Schizophrenia. , 525-539.
CrossRef18
John W. Newcomer, Stefan Leucht. 2010. Metabolic Adverse Effects Associated with Antipsychotic Medications. , 577-597.
CrossRef19
Wolfgang Gaebel, Andreas Schreiner, Paul Bergmans, Rosario de Arce, Frédéric Rouillon, Joachim Cordes, Lars Eriksson, Enrico Smeraldi. (2010) Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial. Neuropsychopharmacology 35:12, 2367-2377
CrossRef20
Diego Novick, Josep Maria Haro, Jordan Bertsch, Peter M. Haddad. (2010) Incidence of Extrapyramidal Symptoms and Tardive Dyskinesia in Schizophrenia. Journal of Clinical Psychopharmacology 30:5, 531-540
CrossRef21
Marcelo Valencia, Maria Luisa Rascon, Francisco Juarez, Raul Escamilla, Ricardo Saracco, Robert Paul Liberman. (2010) Application in Mexico of Psychosocial Rehabilitation with Schizophrenia Patients. Psychiatry: Interpersonal & Biological Processes 73:3, 248-263
CrossRef22
Marja Hensen, Bart Heeg, Mickael Löthgren, Ben van Hout. (2010) Cost Effectiveness of Long-Acting Risperidone in Sweden. Applied Health Economics and Health Policy 8:5, 327-341
CrossRef23
A. Carlo Altamura, Ira D. Glick. (2010) Designing outcome studies to determine efficacy and safety of antipsychotics for ‘real world’ treatment of schizophrenia. The International Journal of Neuropsychopharmacology 13:07, 971-973
CrossRef24
J.P. Docherty, R.A. Baker, J. Eudicone, S. Mathew, R.N. Marcus, R.D. McQuade, R. Mankoski. (2010) Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. Schizophrenia Research 120:1-3, 199-203
CrossRef25
Mingqing Xu, Sheng Li, Qinghe Xing, Rui Gao, Guoyin Feng, Zhiguang Lin, David St Clair, Lin He. (2010) Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study. European Journal of Human Genetics 18:6, 707-712
CrossRef26
Yu-Tao Xiang, Chuan-Yue Wang, Yong-Zhen Weng, Qi-Jing Bo, Helen F.K. Chiu, Jing-Ping Zhao, Tie-Qiao Liu, Sandra S.M. Chan, Edwin H.M. Lee, Gabor S. Ungvari. (2010) Sex differences in patients with schizophrenia: A prospective, multi-center study. Psychiatry Research 177:3, 294-298
CrossRef27
Oleksandr Napryeyenko, Benjaminas Burba, Guadalupe Martinez, Nikolay G. Neznanov, Tsvi Fischel, Franck J. Baylé, Giulio Corrivetti, Enrico Smeraldi, Jonathan Rabinowitz, Andreas Schreiner. (2010) Risperidone Long-Acting Injectable in Recent-Onset Schizophrenia Examined With Clinician and Patient Self-Report Measures. Journal of Clinical Psychopharmacology 30:2, 200-202
CrossRef28
Keith Lloyd, Muhammud A. Latif, Steve Simpson, Keshar L. Shrestha. (2010) Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. Human Psychopharmacology: Clinical and Experimental 25:3, 243-252
CrossRef29
Swapna Verma, Mythily Subramaniam, Edimansyah Abdin, Kang Sim, Alex Su, Nelson Lee, Siow Ann Chong. (2010) Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: A 6-month open-label trial in Asian patients. Human Psychopharmacology: Clinical and Experimental 25:3, 230-235
CrossRef30
Ranganath D Rattehalli, Mahesh B Jayaram, Michael Smith, Ranganath D Rattehalli. 2010. Risperidone versus placebo for schizophrenia. .
CrossRef31
R. W. Buchanan, J. Kreyenbuhl, D. L. Kelly, J. M. Noel, D. L. Boggs, B. A. Fischer, S. Himelhoch, B. Fang, E. Peterson, P. R. Aquino, W. Keller. (2010) The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophrenia Bulletin 36:1, 71-93
CrossRef32
Chad A. Noggle, Raymond S. Dean. (2009) Atypical and typical antipsychotics in the schools. Psychology in the Schools 46:9, 869-884
CrossRef33
Jesús De la Gándara, Luis San Molina, Gabriel Rubio, Alexander Rodriguez-Morales, Rebeca Hidalgo Borrajo, José Antonio Burón. (2009) Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study. Expert Review of Neurotherapeutics 9:10, 1463-1474
CrossRef34
Jihyung Hong, Frank Windmeijer, Diego Novick, Josep Maria Haro, Jacqueline Brown. (2009) The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33:5, 835-841
CrossRef35
J. Rabinowitz, S. Z. Levine, O. Barkai, O. Davidov. (2009) Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features. Schizophrenia Bulletin 35:4, 775-788
CrossRef36
S. Leucht, W. Kissling, J. M. Davis. (2009) How to read and understand and use systematic reviews and meta-analyses. Acta Psychiatrica Scandinavica 119:6, 443-450
CrossRef37
J. Palazzolo. (2009) Observance médicamenteuse et rechutes dans la schizophrénie : des neuroleptiques classiques aux APAP. Annales Médico-psychologiques, revue psychiatrique 167:4, 308-317
CrossRef38
David B. Allison, John W. Newcomer, Andrea L. Dunn, James A. Blumenthal, Anthony N. Fabricatore, Gail L. Daumit, Mark B. Cope, William T. Riley, Betty Vreeland, Joseph R. Hibbeln, Jonathan E. Alpert. (2009) Obesity Among Those with Mental Disorders. American Journal of Preventive Medicine 36:4, 341-350
CrossRef39
J. Peuskens, B. Gillain, D. De Graeve, B. Van Vleymen, A. Albert. (2009) Belgian Schizophrenia Outcome Survey – Results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. European Psychiatry 24:3, 154-163
CrossRef40
Pierre Thomas, Köksal Alptekin, Mihai Gheorghe, Mauro Mauri, José Manuel Olivares, Michael Riedel. (2009) Management of Patients Presenting with Acute Psychotic Episodes of Schizophrenia. CNS Drugs 23:3, 193-212
CrossRef41
Bart Heeg, Erik Buskens, Marc Botteman, Sue Caleo, Mike Ingham, Joep Damen, Frank de Charro, Ben van Hout. (2008) The Cost-Effectiveness of Atypicals in the UK. Value in Health 11:7, 1007-1021
CrossRef42
Shelly Tadger, Yehuda Baruch, Yoram Barak. (2008) Symptomatic remission in elderly schizophrenia patients treated with long-acting risperidone. International Psychogeriatrics 20:06, 1245
CrossRef43
Wolfgang Wölwer, Jürgen Brinkmeyer, Mathias Riesbeck, Lena Freimüller, Ansgar Klimke, Michael Wagner, Hans-Jürgen Möller, Stefan Klingberg, Wolfgang Gaebel, . (2008) Neuropsychological impairments predict the clinical course in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 258:S5, 28-34
CrossRef44
Robin Emsley, Joris Berwaerts, Mariëlle Eerdekens, Michelle Kramer, Rosanne Lane, Pilar Lim, David Hough, Joseph Palumbo. (2008) Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. International Clinical Psychopharmacology 23:6, 343-356
CrossRef45
Hans-Jürgen Möller, Michael Riedel, Markus Jäger, Florian Wickelmaier, Wolfgang Maier, Kai-Uwe Kühn, Gerhard Buchkremer, Isabella Heuser, Joachim Klosterkötter, Markus Gastpar, Dieter F. Braus, Ralf Schlösser, Frank Schneider, Christian Ohmann, Mathias Riesbeck, Wolfgang Gaebel. (2008) Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. The International Journal of Neuropsychopharmacology 11:07,
CrossRef46
Robin Emsley, Petrus Oosthuizen, Liezl Koen, Dana J.H. Niehaus, Rossella Medori, Jonathan Rabinowitz. (2008) Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. International Clinical Psychopharmacology 23:6, 325-331
CrossRef47
Chee Kok Yoon. (2008) Weight Gain and First-Generation Antipsychotics. Journal of Clinical Psychopharmacology 28:5, 574-576
CrossRef48
Frédéric Rouillon, Florence Chartier, Isabelle Gasquet. (2008) Strategies of treatment with olanzapine in schizophrenic patients during stable phase: Results of a pilot study. European Neuropsychopharmacology 18:9, 646-652
CrossRef49
Susan Shur-Fen Gau, Ching-Hu Chung, Churn-Shiouh Gau. (2008) A Pharmacoeconomic Analysis of Atypical Antipsychotics and Haloperidol in First-Episode Schizophrenic Patients in Taiwan. Journal of Clinical Psychopharmacology 28:3, 271-278
CrossRef50
Robin Emsley, Rossella Medori, Liezl Koen, Petrus Paulus Oosthuizen, Dana J.H. Niehaus, Jonathan Rabinowitz. (2008) Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset Psychosis. Journal of Clinical Psychopharmacology 28:2, 210-213
CrossRef51
P.-M. Llorca, P. Bouhours, V. Moreau-Mallet. (2008) Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone. L'Encéphale 34:2, 170-178
CrossRef52
Lakshmi P Voruganti, Laura K Baker, A George Awad. (2008) New generation antipsychotic drugs and compliance behaviour. Current Opinion in Psychiatry 21:2, 133-139
CrossRef53
B. M. S. Heeg, J. Antunes, M. L. Figueira, J. M. Jara, J. Marques Teixeira, A. P. Palha, A. Vaz Serra, E. Buskens, S. Caleo, C. Gouveia-Pinto, B. A. Van Hout. (2008) Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise. Current Medical Research and Opinion 24:2, 349-358
CrossRef54
Vivek A Furtado, Vinod Srihari, Ajit Kumar, Vivek A Furtado. 2008. Atypical antipsychotics for people with both schizophrenia and depression. .
CrossRef55
Mario Álvarez-Jiménez, César González-Blanch, Benedicto Crespo-Facorro, Sarah Hetrick, Jose Manuel Rodríguez-Sánchez, Rocio Pérez-Iglesias, Jose Luis Vázquez-Barquero. (2008) Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders. CNS Drugs 22:7, 547-562
CrossRef56
M. Obradovic, A. Mrhar, M. Kos. (2007) Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. International Journal of Clinical Practice 61:12, 1979-1988
CrossRef57
T. Burns, D. Patrick. (2007) Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatrica Scandinavica 116:6, 403-418
CrossRef58
Saddichha Sahoo, Biswaranjan Mishra, Sayeed Akhtar. (2007) Dose-dependent acute excessive weight gain and metabolic changes in a drug-naive patient on risperidone are reversible with discontinuation: a case report. British Journal of Clinical Pharmacology 64:5, 715-716
CrossRef59
L. N. Yatham, A. Fallu, C. E. Binder. (2007) A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatrica Scandinavica 116:s434, 50-56
CrossRef60
Qinghe Xing, Xueqing Qian, Huafang Li, Shiming Wong, Shengnan Wu, Guoyin Feng, Shiwei Duan, Mingqing Xu, Rui Gao, Wei Qin, Jianjun Gao, Junwei Meng, Lin He. (2007) The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. The International Journal of Neuropsychopharmacology 10:05,
CrossRef61
A. Carlo Altamura, William V. Bobo, Herbert Y. Meltzer. (2007) Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. International Clinical Psychopharmacology 22:5, 249-267
CrossRef62
Yoshiaki Okamoto, Satoru Tsuneto, Yoichi Matsuda, Takaya Inoue, Hitoshi Tanimukai, Keiko Tazumi, Yumiko Ono, Nobuo Kurokawa, Etsuko Uejima. (2007) A Retrospective Chart Review of the Antiemetic Effectiveness of Risperidone in Refractory Opioid-Induced Nausea and Vomiting in Advanced Cancer Patients. Journal of Pain and Symptom Management 34:2, 217-222
CrossRef63
Marc De Hert, Martien Wampers, Ruud van Winkel, Jozef Peuskens. (2007) Anticholinergic use in hospitalised schizophrenic patients in Belgium. Psychiatry Research 152:2-3, 165-172
CrossRef64
Mark Bounthavong, Mark P. Okamoto. (2007) Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. Journal of Evaluation in Clinical Practice 13:3, 453-460
CrossRef65
P. Vandel. (2007) Observance. L'Encéphale 33:3, S399-S401
CrossRef66
M. Neovius, J. Eberhard, E. Lindström, S. Levander. (2007) Weight development in patients treated with risperidone: a 5-year naturalistic study. Acta Psychiatrica Scandinavica 115:4, 277-285
CrossRef67
Robert Rosenheck, Marvin Swartz, Joseph McEvoy, T Scott Stroup, Sonia Davis, Richard SE Keefe, John Hsiao, Jeffrey Lieberman. (2007) Second-generation antipsychotics: reviewing the cost–effectiveness component of the CATIE trial. Expert Review of Pharmacoeconomics & Outcomes Research 7:2, 103-111
CrossRef68
Tiemo Wessels, Dandy Grünler, Christa Bunk, Michael Specka, Markus Gastpar, Norbert Scherbaum, Eugen Davids. (2007) Changes in the Treatment of Acute Psychosis in a German Public Hospital from 1998 to 2004. Psychiatric Quarterly 78:2, 91-99
CrossRef69
Zafar Sharif, Seiya Miyamoto, Jeffrey A. Lieberman. 2007. Pharmacotherapy of Schizophrenia. .
CrossRef70
Gary Remington. (2007) Tardive dyskinesia: eliminated, forgotten, or overshadowed?. Current Opinion in Psychiatry 20:2, 131-137
CrossRef71
Tadashi Nishikawa, Teruo Hayashi, Itsuyuki Koga, Yasunori Uchida. (2007) Neuroleptic Withdrawal with Remitted Schizophrenics: A Naturalistic Follow–Up Study. Psychiatry: Interpersonal & Biological Processes 70:1, 68-79
CrossRef72
Pierre Thomas. (2007) The stable patient with schizophrenia — From antipsychotic effectiveness to adherence. European Neuropsychopharmacology 17, S115-S122
CrossRef73
D. Addington, M. D. Jean Addington, S. Patten. (2007) Relapse rates in an early psychosis treatment service. Acta Psychiatrica Scandinavica 115:2, 126-131
CrossRef74
Michelle Kramer, George Simpson, Valentinas Maciulis, Stuart Kushner, Ujjwala Vijapurkar, Pilar Lim, Mari??lle Eerdekens. (2007) Paliperidone Extended-Release Tablets for Prevention of Symptom Recurrence in Patients With Schizophrenia. Journal of Clinical Psychopharmacology 27:1, 6-14
CrossRef75
MARI MURASHITA, TAKESHI INOUE, ICHIRO KUSUMI, SHIN NAKAGAWA, KOUICHI ITOH, TERUAKI TANAKA, TAKESHI IZUMI, HIROSHI HOSODA, KENJI KANGAWA, TSUKASA KOYAMA. (2007) Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry and Clinical Neurosciences 61:1, 54-58
CrossRef76
Peter M Haddad, Sonu G Sharma. (2007) Adverse Effects of Atypical Antipsychotics. CNS Drugs 21:11, 911-936
CrossRef77
Hans-J??rgen M??ller. (2007) Long-Acting Injectable Risperidone for the Treatment of Schizophrenia. Drugs 67:11, 1541-1566
CrossRef78
William G Honer, Allen E Thornton, Megan Sherwood, G ??William MacEwan, Tom S Ehmann, Richard Williams, Lili C Kopala, Ric Procyshyn, Alasdair M Barr. (2007) Conceptual and Methodological Issues??in the Design of Clinical Trials??of Antipsychotics for the Treatment??of Schizophrenia. CNS Drugs 21:9, 699-714
CrossRef79
Peter F Buckley, Donna A Wirshing, Prameet Bhushan, Joseph M Pierre, Seth A Resnick, William C Wirshing. (2007) Lack of Insight in Schizophrenia. CNS Drugs 21:2, 129-141
CrossRef80
F. Limosin. (2006) Apport des antipsychotiques atypiques dans la prise en charge à long terme de la schizophrénie. L'Encéphale 32:6, 1065-1071
CrossRef81
W. W. Fleischhacker, M. Hummer. (2006) Pharmakotherapie der Schizophrenie. Der Nervenarzt 77:S03, S77-S98
CrossRef82
RAJIV TANDON, STEVEN D. TARGUM, HENRY A. NASRALLAH, RUTH ROSS. (2006) Strategies for Maximizing Clinical Effectiveness in the Treatment of Schizophrenia. Journal of Psychiatric Practice 12:6, 348-363
CrossRef83
Qinghe Xing, Rui Gao, Huafang Li, Guoyin Feng, Mingqing Xu, Shiwei Duan, Junwei Meng, Aiping Zhang, Shengying Qin, Lin He. (2006) Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 7:7, 987-993
CrossRef84
Barrat Luft, David Taylor. (2006) A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opinion on Pharmacotherapy 7:13, 1739-1748
CrossRef85
D. Vincent. (2006) Synthèse à partir de cinq études sur l'efficacité et la tolérance de la rispéridone à action prolongée. Annales Médico-psychologiques, revue psychiatrique 164:7, 634-641
CrossRef86
Corrado Barbui, Camilla Lintas. (2006) Decision models in the evaluation of psychotropic drugs. The European Journal of Health Economics 7:3, 218-220
CrossRef87
Georges M. Gharabawi, Robert A. Lasser, Cynthia A. Bossie, Young Zhu, Xavier Amador. (2006) Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone. International Clinical Psychopharmacology 21:4, 233-240
CrossRef88
Matcheri S. Keshavan, Mary Roberts, Daniela Wittmann. (2006) Guidelines for clinical treatment of early course schizophrenia. Current Psychiatry Reports 8:4, 329-334
CrossRef89
Hans-Jürgen Möller. (2006) Long-acting risperidone: Focus on safety. Clinical Therapeutics 28:5, 633-651
CrossRef90
Douglas A. Smith, Peter F. Buckley. (2006) Pharmacotherapy of delusional disorders in the context of offending and the potential for compulsory treatment. Behavioral Sciences & the Law 24:3, 351-367
CrossRef91
Gabriel Rubio, Agustín Gómez-de-la-Cámara, Francisco Ledesma, José A. Burón, Alexander Rodríguez-Morales, Guadalupe Martínez-Junquera. (2006) Evaluación del tratamiento antipsicótico como factor de riesgo de diabetes en la esquizofrenia: estudio de casos y controles. Medicina Clínica 126:12, 441-444
CrossRef92
Eduard Parellada. (2006) Clinical experience and management considerations with long-acting risperidone. Current Medical Research and Opinion 22:2, 241-255
CrossRef93
T. Scott Stroup, Wayne M. Alves, Robert M. Hamer, Jeffrey A. Lieberman. (2006) Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nature Reviews Drug Discovery 5:2, 133-146
CrossRef94
Richard Marriott, Wendy Neil, Susie Waddingham, Richard Marriott. 2006. Antipsychotic medication for elderly people with schizophrenia. .
CrossRef95
JEAN-PIERRE LINDENMAYER, MOHAN PARAK, JACK M. GORMAN. (2006) Improved Long-Term Outcome with Long-Acting Risperidone Treatment of Chronic Schizophrenia with Prior Partial Response. Journal of Psychiatric Practice 12:1, 55-57
CrossRef96
Peter Falkai, Thomas Wobrock, Jeffrey Lieberman, Birte Glenthoj, Wagner F. Gattaz, Hans-Jürgen Möller, WFSBP Task Force on Treatment Guide, Peter Falkai, Thomas Wobrock, Jeffrey Lieberman, Birte Glenthoj, Wagner F. Gattaz, Hans-Jürgen Möller, WFSBP Task Force on Treatment Guide. (2006) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia. World Journal of Biological Psychiatry 7:1, 5-40
CrossRef97
Salvatore Gentile. (2006) Long-Term Treatment with Atypical Antipsychotics and the Risk of Weight Gain. Drug Safety 29:4, 303-319
CrossRef98
2006. Neuroleptic drugs. , 2438-2489.
CrossRef99
José Luis R. Martin, Víctor Pérez, Montse Sacristán, Fernando Rodríguez-Artalejo, Cristóbal Martínez, Enric Álvarez. (2006) Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. European Psychiatry 21:1, 11-20
CrossRef100
Josep Maria Haro, Diego Novick, Mark Belger, Peter B. Jones. (2006) Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. European Psychiatry 21:1, 41-47
CrossRef101
SIMON C. BURTON. (2005) Strategies for Improving Adherence to Second-Generation Antipsychotics in Patients with Schizophrenia by Increasing Ease of Use. Journal of Psychiatric Practice 11:6, 369-378
CrossRef102
AKIO HIMEI, TAKEHIKO OKAMURA. (2005) Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects. Psychiatry and Clinical Neurosciences 59:5, 556-562
CrossRef103
Lieberman, Jeffrey A., Stroup, T. Scott, McEvoy, Joseph P., Swartz, Marvin S., Rosenheck, Robert A., Perkins, Diana O., Keefe, Richard S.E., Davis, Sonia M., Davis, Clarence E., Lebowitz, Barry D., Severe, Joanne, Hsiao, John K., . (2005) Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. New England Journal of Medicine 353:12, 1209-1223
Full Text104
Takefumi Suzuki, Hiroyuki Uchida, Hiroyoshi Takeuchi, Kensuke Nomura, Akira Tanabe, Koichiro Watanabe, Gohei Yagi, Haruo Kashima. (2005) Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. Psychopharmacology 181:3, 566-575
CrossRef105
Frank-Gerald Pajonk, Andreas Schreiner, Stefan Peters, Klaus Rettig, Detlef Degner, Eckart R??ther. (2005) Risperidone. Journal of Clinical Psychopharmacology 25:4, 293-300
CrossRef106
Paul J Goodnick. (2005) Higher than Physician’s Desk Reference (US) doses on atypical antipsychotics. Expert Opinion on Drug Safety 4:4, 653-668
CrossRef107
Natalie Ciliberto, Cynthia A. Bossie, Ronald Urioste, Robert A. Lasser. (2005) Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. International Clinical Psychopharmacology 20:4, 207-212
CrossRef108
Jean-Pierre Lindenmayer, Kathleen Jarboe, Cynthia A. Bossie, Young Zhu, Angelika Mehnert, Robert Lasser. (2005) Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. International Clinical Psychopharmacology 20:4, 213-221
CrossRef109
Hans-Jürgen Möller. (2005) Risperidone: a review. Expert Opinion on Pharmacotherapy 6:5, 803-818
CrossRef110
Carllo Gagiano, Stephen Read, Lilian Thorpe, Mariëlle Eerdekens, Ilse Hove. (2005) Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders. Psychopharmacology 179:3, 629-636
CrossRef111
Hans-J??rgen M??ller, Pierre-Michel Llorca, Emilio Sacchetti, Stephen D Martin, Rossella Medori, Eduard Parellada. (2005) Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. International Clinical Psychopharmacology 20:3, 121-130
CrossRef112
Izuru Matsumoto, Yuki Inoue, Takeshi Iwazaki, Geoff Pavey, Brian Dean. (2005) 5-HT2A and muscarinic receptors in schizophrenia: a postmortem study. Neuroscience Letters 379:3, 164-168
CrossRef113
M. Taylor, I. Chaudhry, M. Cross, E. McDonald, P. Miller, L. Pilowsky, P. Strickland, . (2005) Towards consensus in the long-term management of relapse prevention in schizophrenia. Human Psychopharmacology: Clinical and Experimental 20:3, 175-181
CrossRef114
Nick C. Patel, M. Lynn Crismon, Kimberly Hoagwood, Peter S. Jensen. (2005) Unanswered Questions Regarding Atypical Antipsychotic Use in Aggressive Children and Adolescents. Journal of Child and Adolescent Psychopharmacology 15:2, 270-284
CrossRef115
P.M. Llorca, H. Miadi-Fargier, C. Lançon, G. JassoMosqueda, F. Casadebaig, A. Philippe, P. Guillon, A. Mehnert, L.F. Omnès, A. Chicoye, I. Durand-Zaleski. (2005) Analyse coût-efficacité des stratégies de prise en charge des patients schizophrènes : place d’un antipsychotique atypique sous forme injectable à libération prolongée. L'Encéphale 31:2, 235-246
CrossRef116
Ya-Mei Bai, Shun-Chieh Yu, Jen-Yeu Chen, Chih-Yuan Lin, Pesus Chou, Chao-Cheng Lin. (2005) Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. International Clinical Psychopharmacology 20:2, 79-85
CrossRef117
Richard Hodgson, R. Belgamwar, Yasin Al-tawarah, G. MacKenzie. (2005) The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire. Human Psychopharmacology: Clinical and Experimental 20:2, 141-147
CrossRef118
Hsien-Yuan Lane, Cheng-Chun Lee, Yi-Ching Liu, Wen-Ho Chang. (2005) Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics 6:2, 139-149
CrossRef119
Arman Danielyan, Robert A Kowatch. (2005) Management Options for Bipolar Disorder in Children and Adolescents. Pediatric Drugs 7:5, 277-294
CrossRef120
Diana De Graeve, Ann Smet, Angelika Mehnert, Sue Caleo, Houda Miadi-Fargier, Guillermo Jasso Mosqueda, Damien Lecompte, Joseph Peuskens. (2005) Long-acting Risperidone Compared with Oral Olanzapine and Haloperidol Depot in Schizophrenia: a Belgian Cost-effectiveness Analysis. PharmacoEconomics 23:Suppl 1, 35???47
CrossRef121
Bart MS Heeg, Erik Buskens, Martin Knapp, Gerda van Aalst, Pieter JT Dries, Lieuwe de Haan, Ben A van Hout. (2005) Modelling the Treated Course of Schizophrenia: Development of a Discrete Event Simulation Model. PharmacoEconomics 23:Suppl 1, 17???33
CrossRef122
Larry Ereshefsky, Erik Mannaert. (2005) Pharmacokinetic Profile and Clinical Efficacy of Long-Acting Risperidone. Drugs in R & D 6:3, 129-137
CrossRef123
Joseph M Pierre. (2005) Extrapyramidal Symptoms with Atypical Antipsychotics. Drug Safety 28:3, 191-208
CrossRef124
Anne Magnus, Vaughan Carr, Cathrine Mihalopoulos, Rob Carter, Theo Vos. (2005) Assessing cost-effectiveness of drug interventions for schizophrenia. Australian and New Zealand Journal of Psychiatry 39:1-2, 44-54
CrossRef125
John M. Davis, Nancy Chen. (2005) Old versus new: weighing the evidence between the first- and second-generation antipsychotics. European Psychiatry 20:1, 7-14
CrossRef126
(2005) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry 39:1-2, 1-30
CrossRef127
PS Chue, Bart MS Heeg, Erik Buskens, Ben A van Hout. (2005) Modelling the Impact of Compliance on the Costs and Effects of Long-acting Risperidone in Canada. PharmacoEconomics 23:Suppl 1, 62???74
CrossRef128
Deanna L Kelly, Robert R Conley, William T Carpenter. (2005) First-Episode Schizophrenia. Drugs 65:8, 1113-1138
CrossRef129
Theo Vos, Michelle M. Haby, Anne Magnus, Cathrine Mihalopoulos, Gavin Andrews, Rob Carter. (2005) Assessing cost-effectiveness in mental health: helping policy-makers prioritize and plan health services. Australian and New Zealand Journal of Psychiatry 39:8, 701-712
CrossRef130
Gerd Laux, Bart MS Heeg, Ben A van Hout, Angelika Mehnert. (2005) Costs and Effects of Long-acting Risperidone Compared with Oral Atypical and Conventional Depot Formulations in Germany. PharmacoEconomics 23:Suppl 1, 49???61
CrossRef131
John W. Newcomer. (2005) Second-Generation (Atypical) Antipsychotics and Metabolic Effects. CNS Drugs 19:Supplement 1, 1???93
CrossRef132
Erin Danielle Knox, Glen L. Stimmel. (2004) Clinical review of a long-acting, injectable formulation of risperidone. Clinical Therapeutics 26:12, 1994-2002
CrossRef133
John W. Newcomer. (2004) Metabolic risk during antipsychotic treatment. Clinical Therapeutics 26:12, 1936-1946
CrossRef134
Pierre S. Chue, Peter D'Hoore, J. Michael Ramstack. (2004) Sustained drug delivery optimizes long-term treatment of patients with schizophrenia. Acta Neuropsychiatrica 16:6, 319-325
CrossRef135
Robert Lasser, Cynthia A. Bossie, Georges Gharabawi, Marielle Eerdekens, Henry A. Nasrallah. (2004) Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. Journal of Affective Disorders 83:2-3, 263-275
CrossRef136
A. JONES. (2004) Perceptions on the standardization of psychiatric work: development of a care pathway. Journal of Psychiatric and Mental Health Nursing 11:6, 705-713
CrossRef137
&NA;. (2004) Long-acting injectable antipsychotics: a useful and well tolerated option in elderly patients with psychotic illnesses. Drugs & Therapy Perspectives 20:12, 7-10
CrossRef138
A. Leal, D. Rosillon, A. Mehnert, M. Jarema, G. Remington. (2004) Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiology and Drug Safety 13:11, 811-816
CrossRef139
Louise Nash, Joanne Gorrell, Alison Cornish, Alan Rosen, Vivienne Miller, Chris Tennant. (2004) Clinical outcome of an early psychosis intervention program: evaluation in a real-world context. Australian and New Zealand Journal of Psychiatry 38:9, 694-701
CrossRef140
Montserrat Vera-Llonch, Thomas E. Delea, Erin Richardson, Marcia Rupnow, Amy Grogg, Gerry Oster. (2004) Outcomes and Costs of Risperidone versus Olanzapine in Patients with Chronic Schizophrenia or Schizoaffective Disorders: A Markov Model. Value in Health 7:5, 569-584
CrossRef141
Siegfried Kasper, Martin Brecher, Lesley Fitton, Andrew Martin Jones. (2004) Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. International Clinical Psychopharmacology 19:5, 281-289
CrossRef142
Daniel J. Safer. (2004) A Comparison of Risperidone-Induced Weight Gain Across the Age Span. Journal of Clinical Psychopharmacology 24:4, 429-436
CrossRef143
Martin Turner, Els Eerdekens, Mary Jacko, Mariëlle Eerdekens. (2004) Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. International Clinical Psychopharmacology 19:4, 241-249
CrossRef144
J P Lindenmayer, Anzalee Khan. (2004) Pharmacological treatment strategies for schizophrenia. Expert Review of Neurotherapeutics 4:4, 705-723
CrossRef145
Michael A. Reveley, Susan E. Libretto. (2004) Treatment Outcome in Patients With Chronic Schizophrenia During Long-term Administration With Risperidone. Journal of Clinical Psychopharmacology 24:3, 260-267
CrossRef146
Thomas J. Raedler, Andreas Schreiner, Dieter Naber, Klaus Wiedemann. (2004) Risperidone in the Treatment of Acute Schizophrenia. Journal of Clinical Psychopharmacology 24:3, 335-338
CrossRef147
G. J. R. Mensink, C. J. Slooff. (2004) Novel antipsychotics in bipolar and schizoaffective mania. Acta Psychiatrica Scandinavica 109:6, 405-419
CrossRef148
Yemi Aina, Jayasree Nandagopol, Henry A. Nasrallah. (2004) Endocrine disorders in schizophrenia: Relationship to antipsychotic therapy. Current Psychosis and Therapeutics Reports 2:2, 78-83
CrossRef149
Nadeem H. Bhanji, Guy Chouinard, Howard C. Margolese. (2004) A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. European Neuropsychopharmacology 14:2, 87-92
CrossRef150
Roopa Sathyaprakash, Robert R. Henry. (2004) Hyperglycemia with antipsychotic treatment. Current Diabetes Reports 4:1, 41-45
CrossRef151
Heinz Grunze, Siegfried Kasper, Guy Goodwin, Charles Bowden, Hans-ju¨rgen Mo¨ller, WFSBP Task Force on Treatment Guide. (2004) The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part III: Maintenance Treatment. World Journal of Biological Psychiatry 5:3, 120-135
CrossRef152
Frank-Gerald Pajonk. (2004) Risperidone in acute and long-term therapy of schizophrenia—a clinical profile. Progress in Neuro-Psychopharmacology and Biological Psychiatry 28:1, 15-23
CrossRef153
P. Joseph Gibson, Robert Damler, E. Anne Jackson, Teresa Wilder, Janet L. Ramsey. (2004) The Impact of Olanzapine, Risperidone, or Haloperidol on the Cost of Schizophrenia Care in a Medicaid Population. Value in Health 7:1, 22-35
CrossRef154
Ramy A Mahmoud, Luella M Engelhart, Carmela C Janagap, Gerry Oster, Dan Ollendorf. (2004) Risperidone versus Conventional Antipsychotics for Schizophrenia and???Schizoaffective Disorder. Clinical Drug Investigation 24:5, 275-286
CrossRef155
Ann M Mortimer. (2004) Atypical Antipsychotics as First-Line Treatments for Schizophrenia. Disease Management & Health Outcomes 12:3, 169-179
CrossRef156
Bruce J Kinon, Jonna Ahl, Virginia L Stauffer, Angela L Hill, Peter F Buckley. (2004) Dose Response and Atypical Antipsychotics in Schizophrenia. CNS Drugs 18:9, 597-616
CrossRef157
Kazuyuki Fujita, Toshihiko Fukuchi, Shoji Yuasa, Eriko Inada, Yoko Tarao, Kousuke Kanemoto. (2004) Switch from Risperidone to Perospirone in Patients with Chronic Schizophrenia. Clinical Drug Investigation 24:5, 295-299
CrossRef158
Charles M. Beasley, Virginia K. Sutton, Susan H. Hamilton, Daniel J. Walker, Martin Dossenbach, Cindy C. Taylor, Karla J. Alaka, Deborah Bykowski, Gary D. Tollefson. (2003) A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse. Journal of Clinical Psychopharmacology 23:6, 582-594
CrossRef159
A LEHMAN, R BUCHANAN, F DICKERSON, L DIXON, R GOLDBERG, L GREENPADEN, J KREYENBUHL. (2003) Evidence-based treatment for schizophrenia. Psychiatric Clinics of North America 26:4, 939-954
CrossRef160
E. Sacchetti, P. Valsecchi. (2003) Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report. International Clinical Psychopharmacology 18:6, 357-359
CrossRef161
Wood, Alastair J.J., , Freedman, Robert, . (2003) Schizophrenia. New England Journal of Medicine 349:18, 1738-1749
Full Text162
Hsien-Yuan Lane, Yue-Cune Chang, Chieh-Liang Huang, Wen-Ho Chang. (2003) Refining pharmacogenetic research in schizophrenia: Control for patient-related variables. Drug Development Research 60:2, 164-171
CrossRef163
Prakash S Masand, Sanjay Gupta. (2003) Quality of life issues associated with antipsychotic-induced weight gain. Expert Review of Pharmacoeconomics & Outcomes Research 3:5, 651-659
CrossRef164
Nicholas Keks, Cyril Been, Russell D’Souza, Rajan Thomas, Philip Tune, Jenny Babb, Edwina Brennan, Judy Hope. (2003) Initial experience with long-acting risperidone microspheres injection. Australasian Psychiatry 11:3, 273-275
CrossRef165
S. Tardieu, J. Micallef, S. Gentile, O. Blin. (2003) Weight gain profiles of new anti-psychotics: public health consequences. Obesity Reviews 4:3, 129-138
CrossRef166
JV Lucey, SE Libretto. (2003) Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis. Irish Journal of Medical Science 172:4, 195-201
CrossRef167
John Geddes, Paul Harrison, Nick Freemantle. (2003) New generation versus conventional antipsychotics. The Lancet 362:9381, 404
CrossRef168
Pierre Chue. (2003) Risperidone long-acting injection. Expert Review of Neurotherapeutics 3:4, 435-446
CrossRef169
Patrick McGorry, Eoin Killackey, Kathryn Elkins, Martin Lambert, Tim Lambert. (2003) Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia (2003). Australasian Psychiatry 11:2, 136-147
CrossRef170
Ray, Wayne A., Daugherty, James R., Meador, Keith G., . (2003) Effect of a Mental Health “Carve-Out” Program on the Continuity of Antipsychotic Therapy. New England Journal of Medicine 348:19, 1885-1894
Full Text171
Robert Hunter, Eilis Kennedy, Fujian Song, Lisa Gadon, Claire B Irving, Robert Hunter. 2003. Risperidone versus typical antipsychotic medication for schizophrenia. .
CrossRef172
&NA;. (2003) Recommendations. Current Opinion in Psychiatry 16, S21-S28
CrossRef173
R EMSLEY, P OOSTHUIZEN. (2003) The new and evolving pharmacotherapy of schizophrenia. Psychiatric Clinics of North America 26:1, 141-163
CrossRef174
J LAURIELLO, R LENROOT, J BUSTILLO. (2003) Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia. Psychiatric Clinics of North America 26:1, 191-211
CrossRef175
James L. Karagianis, Kellie K. LeDrew, Daniel J. Walker. (2003) Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up*. Current Medical Research and Opinion 19:6, 473-480
CrossRef176
Adrián LLerena, Roland Berecz, Pedro Dorado, César Sanz de la Garza, Marı́a Jesús Norberto, Macarena Cáceres, José Ramón Gutiérrez. (2003) Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. Journal of Chromatography B 783:1, 213-219
CrossRef177
Stephen D. Martin, Susan E. Libretto, David J. Pratt, J. S. Brewin, Zahid-ul Huq, B. T. Saleh. (2003) Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Current Medical Research and Opinion 19:4, 298-305
CrossRef178
Prakash S Masand, Sanjay Gupta. (2003) Long-Acting Injectable Antipsychotics in the Elderly. Drugs & Aging 20:15, 1099-1110
CrossRef179
Hans-J??rgen M??ller. (2003) Management of the Negative Symptoms of Schizophrenia. CNS Drugs 17:11, 793-823
CrossRef180
Jambur Anath, Ravi Venkatesh, Karl Burgoyne, Davin Augustines, Virginia Corpuz, Sarath Gunatilake. (2003) Weight gain associated with atypical antipsychotic drugs: mechanisms and management. Expert Review of Neurotherapeutics 3:1, 59-68
CrossRef181
Patrick D. McGorry, Eoin J. Killackey. (2002) Early intervention in psychosis: a new evidence based paradigm. Epidemiologia e Psichiatria Sociale 11:04, 237-247
CrossRef182
. (2002) Risperidon en haloperidol ter preventie van recidieven bij schizofrenie. Medisch-Farmaceutische Mededelingen 40:6, 160-161
CrossRef183
(2002) Current Awareness. Human Psychopharmacology: Clinical and Experimental 17:4, 201-212
CrossRef184
(2002) Prevention of Relapse in Schizophrenia. New England Journal of Medicine 346:18, 1412-1413
Full Text185
Christian Otte, Dieter Naber. (2002) Atypical antipsychotics in the treatment of schizophrenic patients. Expert Review of Neurotherapeutics 2:3, 355-362
CrossRef186
&NA;. (2002) II The usefulness of the second-generation antipsychotic medications. Current Opinion in Psychiatry 15, S7-S16
CrossRef187
&NA;. (2002) III The context for the use of the second-generation antipsychotic medications: opportunities and constraints. Current Opinion in Psychiatry 15, S17-S23
CrossRef188
Geddes, John, . (2002) Prevention of Relapse in Schizophrenia. New England Journal of Medicine 346:1, 56-58
Full Text189
John G. Csernansky, Emily K. Schuchart. (2002) Relapse and Rehospitalisation Rates in Patients with Schizophrenia. CNS Drugs 16:7, 473-484
CrossRef190
&NA;. (2002) Risperidone superior at preventing relapse in schizophrenia. Inpharma Weekly &NA;:1320, 15
CrossRef191
Y. Lecrubier. (2002) Amisulpride: Progress and Outcomes. Current Medical Research and Opinion 18:s3, s18-s22
CrossRef
